The Medical Executive Q&A: CardioGenics’ Yahia Gawad

Submitted by admin on Mon, 01/04/2010 - 09:46
To ER staff treating the 58-year-old man just wheeled through the hospital doors after Christmas dinner, determining whether his symptoms are a result of holiday overindulgence or arterial blockage is literally a life-and-death matter.

Yahia Gawad has designed his company’s cardiac diagnostic test for that moment. The founder and CEO of CardioGenics (Mississauga, ON, Canada) claims the QL Care Analyzer offers highly accurate, rapid results at a sensitivity level heretofore unavailable in the POC immunoassay market. The device is the first of its kind to use chemiluminescence outside of a large lab analyzer, he says. This capability is particularly acute at a time of evolving definitions of ischemia, a growing need for more-sensitive tests, and increasing pressure to pare healthcare costs. (Read More)

Source: Medical Device Link

Market Data